Niacin drug beats Zetia in study of cholesterol treatments
Merck & Co.'s Zetia failed to outperform Niaspan, a modified form of vitamin B, in reducing plaque buildup in arteries and boosting the level of HDL, or "good" cholesterol, in a study of 200 patients taking statins. Merck officials and critics of the study downplayed the findings, saying the trial examined only the amount of plaque on artery walls, a surrogate marker, and not the rate of heart attack or stroke.
Washington Post, The
| 11/16
This story published in FMI Pharmacy dailyLead on 11/16/2009
Get stories like these delivered daily for FREE:
|
FMI Pharmacy dailyLead
Designed specifically for pharmacy professionals, FMI Pharmacy dailyLead is a FREE, daily e-mail newsletter. It provides the latest news in the pharmacy arena. Learn more |
|